Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Petrofac delays results as it progresses restructuring plan

(Sharecast News) - Petrofac said in an update on Friday that a UK court has approved the proposed creditor class composition for its financial restructuring plan, allowing it to proceed with creditor meetings. The London-listed firm said a sanction hearing was scheduled to take place between 30 April and 2 May, with the restructuring expected to become effective shortly thereafter.

As a result, Petrofac said it had postponed the publication of its audited 2024 results until after the restructuring was complete.

Trading in the company's shares would be temporarily suspended from 1 May, in line with listing requirements, and would resume once the results were released.

The company also confirmed that the subscription period opened on 12 March, enabling secured creditors to participate in the new money options set out in the restructuring plan.

In addition, Petrofac reiterated its support for retail shareholders potentially affected by the restructuring.

It encouraged those who held shares between 7 October 2005 and 5 October 2021 to contact independent representative Jon Yorke to assess whether they could have a claim, noting that doing so would not affect their legal rights.

At 0839 GMT, shares in Petrofac were up 0.16% at 6.12p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.